Corvus Pharmaceuticals vs Pliant Therapeutics
CRVS and PLRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVS and PLRX compare
Corvus Pharmaceuticals is the larger company, worth 21 times as much as Pliant Therapeutics ($895M against $43.2M).
Corvus Pharmaceuticals scores higher on the StockData Score (7 against 6 for Pliant Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVS | PLRX |
|---|---|---|
| Size and price | ||
| Market cap | $895M | $43.2M |
| Share price | $10.64 | $0.697 |
| Change, 1 year | 30.1% | −61.3% |
| Change, 5 years | 204% | −95.4% |
| Beta (5Y) | 1.17 | 1.00 |
| Employees | 37 | 49 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.3× | 0.3× (better) |
| FCF yield | −5.4% (better) | −155% |
| Profitability | ||
| Return on equity | −45.9% (better) | −55.3% |
| Return on invested capital | −932% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −698.2× |
| Current ratio | 13.38 (better) | 8.05 |
| Altman Z-score | 31.64 (better) | −7.99 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.1% | 77.7% |
| Held by insiders | 30.5% | 13.0% |
| Insider net buying, 12 months | $334K (better) | −$164K |
| Short interest, % of float | 30.4% | 9.1% |
Go deeper
- CRVS stock overview
- CRVS income statement
- CRVS valuation and score
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.